Company Active LTD

Company profile

Imagen Therapeutics Limited

imagentherapeutics.com

Imagen Therapeutics Limited is a UK company with status active founded in 2007.

CRN
06373341
Founded
2007
Age
18

Overview

Legal name
IMAGEN THERAPEUTICS LIMITED
Region
Unknown
Registered address
PEARL ASSURANCE HOUSE
319 BALLARDS LANE
LONDON
N12 8LY
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
01 Oct
2023

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2023

Accounts due

Accounts Due

Next accounts due date

17 Sep
2022

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2021

Accounts filed

Accounts

Last accounts made up date

17 Sep
2007

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2013
Funded years
2013, 2017
Age at first award
5 years

Projects

2017 Feasibility Studies Lead participant

The personalisation of paedatric Oncology using Phenotypic High Content Analysis

1 Jul 2017 to 31 Jan 2019

Awarded
£59,531
Total cost £85,044

Thankfully, 80% of children's cancers are well treated with modern therapy. However, the remaining 20% suffer a high degree of poor health and mortality with many second and third line treatments offering very little benefit. This is despite the fact that there has been a very rapid increase in the number of potential chemotherapies that are available for...

2013 Feasibility Studies Lead participant

The use of High Content Phenotypic screening to guide the clinical management of cancer treatment.

1 Sep 2013 to 28 Feb 2014

Awarded
£42,290
Total cost £56,387

Beating cancer requires a treatment that kills cancer cells but leaves normal tissue unharmed. While this seems simple enough it is actually very difficult because cancer cells look so much like normal cells when it comes to treating with anti-cancer drugs. The drugs that are available to treat cancer all aim to target cancer cells in preference to normal...

Product types

Feasibility Studies